Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib + Chemo in Metastatic TNBC (PRESERVE 2)
NCT04799249Phase 3Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of trilaciclib in triple negative breast cancer (TNBC), sponsored by G1 Therapeutics, Inc.. Started May 2021; status: completed.
02
Drugs
trilaciclib
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04799249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799249.